Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 2:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–20 of 20 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Comparison of two standard of care regimens Clear all
Completed Phase 4 Interventional

CGM - Reimagine Primary Care

NCT04413578
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Dexcom G6, Contour NextOne
Device
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years to 80 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
4
States / cities
Holladay, Utah • Murray, Utah • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 3, 2020 · Synced Sep 29, 2026, 2:49 AM EDT
Completed Not applicable Interventional

The Use of Serratus Block for Cardiac Surgery

NCT03237546
View directory record Official record
Conditions
Cardiac Surgery
Interventions
Anesthetic regimen including SB, Anesthetic regimen including SB or no block
Procedure
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 100 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 28, 2018 · Synced Sep 29, 2026, 2:49 AM EDT
Completed Phase 3 Interventional Results available

A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed Therapy

NCT01419197
View directory record Official record
Conditions
Breast Cancer
Interventions
Trastuzumab emtansine, Treatment of physician's choice
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
602 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
59
States / cities
Tucson, Arizona • Hot Springs, Arkansas • Hayward, California + 52 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2016 · Synced Sep 29, 2026, 2:49 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Tobacco Treatment Outreach to Reduce Disparities for Primary Care Populations

NCT01156610
View directory record Official record
Conditions
Smoking, Smoking Cessation
Interventions
Tobacco Treatment
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
706 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 5, 2014 · Synced Sep 29, 2026, 2:49 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of BCT197 in Subjects With Acute Respiratory Exacerbations of Chronic Obstructive Pulmonary Disease

NCT02700919
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
BCT197, Placebo
Drug
Lead sponsor
Mereo BioPharma
Industry
Eligibility
40 Years and older
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
3
States / cities
Michigan City, Indiana • Baltimore, Maryland • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 29, 2020 · Synced Sep 29, 2026, 2:49 AM EDT
Completed Phase 4 Interventional Results available

Randomized Conversion of Calcineurin-Inhibitors in Renal Allograft Recipients

NCT00866879
View directory record Official record
Conditions
Renal Transplant Rejection
Interventions
Sirolimus, Demographic Data, Medical History, and Donor Data, Blood Draws for Control Group, Blood Draws for Experimental Group, Donor Blood Draws, Donor Information, Kidney Biopsy
Drug · Other · Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 70 Years
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 27, 2019 · Synced Sep 29, 2026, 2:49 AM EDT
Recruiting Not applicable Interventional

Participatory Approaches to Qualitative Research (PAQ): Comparing Two Approaches to Patient, Public and Clinician Involvement in Qualitative Research

NCT06838689
View directory record Official record
Conditions
Pediatric Mental Health Services, Cancer Screening, Serious Illness
Interventions
Comparison of two standard of care regimens
Other
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Hanover, New Hampshire • Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Sep 29, 2026, 2:49 AM EDT
Terminated No phase listed Observational

Comparison of Standard of Care Guidelines for Mycoplasma Genitalium Infections Among Men With Non-gonococcal Urethritis

NCT03910907
View directory record Official record
Conditions
Mycoplasma Genitalium Infection
Interventions
Comparison of two standard of care regimens
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 99 Years · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 1, 2023 · Synced Sep 29, 2026, 2:49 AM EDT
Active, not recruiting No phase listed Observational

Feasibility and Acceptance of SonoHeal for Airway Clearance and Preliminary Comparison With the Standard of Care

NCT07568119
View directory record Official record
Conditions
Cystic Fibrosis (CF), Non Cystic Fibrosis Bronchiectasis, Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Airway clearance therapy through acoustic oscillations
Device
Lead sponsor
Cognita Labs LLC
Industry
Eligibility
11 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Santa Ana, California
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Sep 29, 2026, 2:49 AM EDT
Withdrawn Phase 2 Interventional

Selective CD28 Blockade in Renal Transplant Recipients

NCT04903054
View directory record Official record
Conditions
Kidney Transplantation, Renal Transplant Recipients
Interventions
Lulizumab, Tacrolimus, Thymoglobulin®, Methylprednisolone, Mycophenolate Mofetil, Prednisone
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 21, 2023 · Synced Sep 29, 2026, 2:49 AM EDT
Completed Phase 3 Interventional Results available

Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

NCT02741570
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Nivolumab, Ipilimumab, Cetuximab/Erbitux, Cisplatin/Platinol, Carboplatin/Paraplatin, Fluorouracil/Adrucil
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
947 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
22
States / cities
Tucson, Arizona • Duarte, California • Stanford, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2023 · Synced Sep 29, 2026, 2:49 AM EDT
Completed Phase 4 Interventional Results available

Belatacept 3 Month Post Transplant Conversion Study

NCT02213068
View directory record Official record
Conditions
Transplant; Failure, Kidney, EBV
Interventions
belatacept, Tacrolimus, MPA
Drug
Lead sponsor
Lorenzo Gallon
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 7, 2023 · Synced Sep 29, 2026, 2:49 AM EDT
Terminated Phase 2 Interventional Results available

Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Liver Transplant Recipients With Additional 12-month Follow-up and Long-term Extension

NCT03781414
View directory record Official record
Conditions
Liver Transplant Rejection
Interventions
CFZ533, Tacrolimus - MMF - corticosteroids
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
9
States / cities
Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Sep 29, 2026, 2:49 AM EDT
Recruiting Phase 3 Interventional

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

NCT05675410
View directory record Official record
Conditions
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
Interventions
Biospecimen Collection, Bleomycin Sulfate, Brentuximab Vedotin, Computed Tomography, Cyclophosphamide, Dacarbazine, Doxorubicin Hydrochloride, Etoposide, Etoposide Phosphate, Fludeoxyglucose F-18, Involved-site Radiation Therapy, Magnetic Resonance Imaging, Nivolumab, Positron Emission Tomography, Prednisolone, Prednisone, Procarbazine Hydrochloride, Questionnaire Administration, Vinblastine Sulfate, Vincristine Sulfate
Procedure · Biological · Drug + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
5 Years to 60 Years
Enrollment
1,875 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
400
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 296 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Sep 29, 2026, 2:49 AM EDT
Completed Not applicable Interventional

Study of Tongue Strengthening for Swallowing Problems

NCT01570023
View directory record Official record
Conditions
Dysphagia
Interventions
Isometric Progressive Resistance Oropharyngeal Therapy
Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
21 Years to 95 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
9
States / cities
Evanston, Illinois • Lexington, Kentucky • Minneapolis, Minnesota + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2015 · Synced Sep 29, 2026, 2:49 AM EDT
Completed Phase 4 Interventional Results available

Belatacept Early Steroid Withdrawal Trial

NCT01729494
View directory record Official record
Conditions
Renal Transplantation
Interventions
Alemtuzumab, rabbit antithymocyte globulin, Belatacept, Tacrolimus, Mycophenolate mofetil, early cessation of steroids
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
316 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
8
States / cities
San Francisco, California • Denver, Colorado • Tampa, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 29, 2026, 2:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation Of The Pharmacokinetics Of Antithrombin III In Neonates And Infants Undergoing CPB And ECMO Support

NCT02631174
View directory record Official record
Conditions
Extracorporeal Membrane Oxygenation Complication, Cardiopulmonary Bypass
Interventions
Antithrombin III
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Up to 1 Year
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 24, 2019 · Synced Sep 29, 2026, 2:49 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of Liver and Cardiometabolic Health Benefits on Low Carbohydrate Ketogenic Diet

NCT03141008
View directory record Official record
Conditions
Obesity, Fatty Liver, Ketogenic Dieting
Interventions
Fibroscan changes with different diets
Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 9, 2020 · Synced Sep 29, 2026, 2:49 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Split Face Study of the Effects of Micro Needling With and Without Platelet Rich Plasma

NCT04219293
View directory record Official record
Conditions
Aging
Interventions
Microneedling w/ and w/o PRP
Device
Lead sponsor
Dallas Plastic Surgery Institute
Other
Eligibility
30 Years to 60 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 10, 2021 · Synced Sep 29, 2026, 2:49 AM EDT
Not yet recruiting Phase 4 Interventional

Comparing Different Medication Regimens to Maintaining Weight Loss Among Adults With Obesity Using GLP-1s

NCT07832084
View directory record Official record
Conditions
Obesity & Overweight, Cardiometabolic Health Indicators
Interventions
GLP-1 dose reduction, non-GLP weight loss medication, Maintenance of GLP-1 dose, Resistance exercise regimen, Lifestyle/nutrition counseling
Drug · Behavioral
Lead sponsor
Jing Luo
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 20, 2026 · Synced Sep 29, 2026, 2:49 AM EDT